Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
Noosa News23 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General20 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Business23 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000
-
Noosa News23 hours agoGrow it local | Noosa Today